| V-Notes Hysterectomy in Patients With Endometrial cáncer Compared With Laparoscopic Surgery (Robotically Assisted or Not): ENOLA TRIAL (NCT07074067) | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 2022-07-11 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601) | National Cancer Institute (NCI) | 2022-06-02 |
| PErsonalized TReatment for Endometrial Carcinoma (NCT05655260) | University of Helsinki | 2022-02-08 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer (NCT04972682) | Moscow City Oncology Hospital No. 62 | 2021-07-01 |
| Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies (NCT04873206) | Sohag University | 2020-01-01 |
| Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment (NCT04106414) | Memorial Sloan Kettering Cancer Center | 2019-09-24 |
| Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma (NCT03716414) | Fudan University | 2018-11-01 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826) | National Cancer Institute (NCI) | 2018-09-27 |
| Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care (NCT03460483) | Ohio State University Comprehensive Cancer Center | 2018-03-30 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Pembro/Carbo/Taxol in Endometrial Cancer (NCT02549209) | Daniela Matei, MD | 2017-08-22 |
| Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines (NCT03164590) | Assiut University | 2017-06-01 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer (NCT02065687) | Gynecologic Oncology Group | 2014-03-17 |
| Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer (NCT01943058) | University of Southern California | 2014-03-01 |
| Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma (NCT01968317) | Xiaojun Chen | 2013-10-01 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973) | National Cancer Institute (NCI) | 2013-09-30 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01642082) | Gynecologic Oncology Group | 2012-09-01 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01225887) | Gynecologic Oncology Group | 2011-10-01 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer (NCT01307631) | National Cancer Institute (NCI) | 2011-03-01 |
| Prognostic Biomarkers in Patients With Endometrial Cancer (NCT01208467) | Gynecologic Oncology Group | 2010-09-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01132820) | National Cancer Institute (NCI) | 2010-06-01 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (NCT01005329) | National Cancer Institute (NCI) | 2009-11-06 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574) | National Cancer Institute (NCI) | 2009-09-14 |
| Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01011933) | National Cancer Institute (NCI) | 2009-09-01 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00814086) | Gynecologic Oncology Group | 2009-02-01 |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00820898) | Gynecologic Oncology Group | 2009-02-01 |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer (NCT01041027) | Albert Einstein College of Medicine | 2009-01-16 |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT00478426) | National Cancer Institute (NCI) | 2007-04-30 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00095979) | National Cancer Institute (NCI) | 2005-05-01 |
| Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus (NCT00064025) | Gynecologic Oncology Group | 2004-04-01 |
| Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00025467) | National Cancer Institute (NCI) | 2001-09-01 |
| Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00006089) | National Cancer Institute (NCI) | 2000-09-18 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00005830) | Gynecologic Oncology Group | 2000-07-01 |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00006011) | Gynecologic Oncology Group | 2000-07-01 |
| Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus (NCT00002706) | Gynecologic Oncology Group | 1996-04-01 |